New set-up for IT at Bayer

BayerBayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses. The realignment is part of the efficiency and structural measures that Bayer announced back in November 2018.

"We're not only looking to achieve savings but to use this opportunity to establish a new set-up for our IT function. The goal is to deliver new solutions in health and agriculture much faster," says Wolfgang Nickl, Chief Financial Officer and member of the Board of Management at Bayer. "The support of external partners is essential for Bayer - and that's why we have chosen leading providers that we are already working with," adds Daniel Hartert, Chief Information Officer at Bayer. The partners will take on around 950 IT employees (full-time equivalents) from Bayer in Germany. The following strategic partners have been selected:

  • Atos for Global Workplace Services and Security Operations
  • Capgemini for Business Intelligence Analytics and Controlling (BIAC), Enterprise Resource Planning (excluding HR), global IT Infrastructure, Service Integration, and Unified Communications & Collaboration
  • Cognizant for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Crop Science Division
  • Tata Consultancy Services for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Consumer Health and Pharmaceuticals divisions, the corporate functions and HR IT

The six-year contract can be extended by one year. The respective employees in Germany will be moving to the partners in the coming months. "Parting ways with so many employees is not easy. However, this change also comes with opportunities. We are convinced that our IT colleagues will have good development prospects with the specialized providers. The respective activities will not be continued at Bayer," says Hartert.

Internally, the Bayer IT function will be organized in agile teams that are closely linked to the businesses. The aim is to digitalize the whole value chain: from research and development to product supply, marketing and sales.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Most Popular Now

ACE2 protein protects against severe COVID-19

Female COVID-19 patients face less severe disease complications and a lower risk of dying than male patients thanks to hormones and chromosomes that contribute to a stron...

Neutralizing antibodies protect against severe COV…

Understanding the body's immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines. Of particular...

How SARS-CoV-2 interacts with cells

SARS-CoV-2 infections pose a global threat to human health and a formidable research challenge. One of the most urgent tasks is to gain a detailed understanding of the mo...

Valneva initiates Phase 1/2 clinical study of inac…

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for it...

Vir Biotechnology and GSK announce start of NIH-sp…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Ins...

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EM...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

Pfizer and BioNTech receive authorization in the E…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...